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described the presence of renin cells in a 
periglomerular interstitial location rather 
than in the classical JG localization.  e 
paper by Schweda  et al. 7 shows that the 
replacement of Cx40 with Cx45 re-estab-
lishes the location of JG cells.  e reloca-
tion of cells in the Cx40   −  /  −   mice can be 
interpreted to suggest that the presence of 
either connexin provides the necessary 
cues for appropriate positional informa-
tion. In this regard, gap junctions are 
known to regulate migration, prolifera-
tion, and adhesion during embryonic 
development. 2,3 Because the distribution 
of renin cells is normal during embryonic 
life in C40   −  /  −   mice and becomes dis-
rupted only later in postnatal life, this 
may argue against an inadequate assem-
bly of renin cells into the vasculature dur-
ing early development. It is more likely 
that the observed presence of renin cells 
in the periglomerular interstitial area and 
in the extraglomerular and glomerular 
mesangium is a return to the embryonic 
and fetal pattern of renin expression. It 
should be noted that in fetal life, renin 
precursors are present in the interstitium, 
and the appearance of renin cells in the 
periglomerular area may re7 ect the capa-
bility of those cells of re-expressing or 
retaining expression of the renin gene 
when the demands of extrauterine life so 
require it to maintain homeostasis. 
In fact, interstitial cells can and do re-
express renin in response to manipula-
tions that in the adult animal threaten 
homeostasis. 13,14 
 Notably, deletion or mutations of sev-
eral genes of the renin – angiotensin system 
in mice and humans, pharmacological 
inhibition of angiotensin actions, as well 
as threats to homeostasis such as hypoten-
sion or dehydration result in the reappear-
ance of renin-expressing cells  in several 
sites, including the interstitium, the 
glomerulus, periglomerular areas, 
and along and around a/ erent arterioles 
( Figure 2 ). 12 – 14 This response  – called 
recruitment  – does not involve cell migra-
tion or replication of cells, and it is a reac-
quisition of cell identity along a 
developmentally and lineage-restricted 
pathway. 12 Whether recruitment upstream 
of the a/ erent arteriole occurs in Cx40   −  /  −  
mice will require further experimentation 
with di/ erent manipulations. 
 It would be of interest to explore which 
connexins are involved in the reacquisition 
of renin-cell identity known to occur in ani-
mals and humans with renin – angiotensin 
system gene mutations resulting in kidney 
abnormalities and / or hypertension. 
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 Engineering parathyroid 
cells to treat secondary 
hyperparathyroidism 
 Mariano  Rodr í guez 1 ,  Julio M.  Martinez-Moreno 1 and  Yolanda  Almad é n 1     
 Kanai  et al. used antisense technology to reduce excessive PTH 
production. The authors have overcome technical difficulties to 
demonstrate that, by strategies of RNA interference, a steady reduction 
of PTH secretion can be induced in cultured parathyroid-cell spheroids 
and in athymic nude mice with hyperplastic parathyroid cells 
transplanted from patients with secondary hyperparathyroidism . 
 Kidney International (2009)  75, 462 – 464.  doi: 10.1038/ki.2008.635 
see original article on page 490
  is commentary focuses on two impor-
tant methodological topics that have been 
addressed in the paper by Kanai  et al. 1 
(this issue) to demonstrate that, by strate-
gies of RNA interference, a steady reduc-
tion of PTH secretion can be induced: 
 rst, the use of an innovative parathyroid 
tissue culture system,  ‘ spheroids, ’ which 
provide a three-dimensional structured 
culture that retains a long-term calcium 
responsiveness; and second, the use of 
small interfering RNA (siRNA) to drive 
the speci c suppression of parathyroid 
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(reviewed by R á cz and Hamar 7 ). Particu-
larly, RNA interference has emerged as a 
promising new therapeutic tool for the 
treatment of diseases involving overex-
pression of a particular gene. Excessive 
production of PTH due to secondary 
hyperparathyroidism appears to be a good 
candidate for this type of gene therapy. 
Kanai  et al. 5 applied this methodology to 
suppress PTH production by cultured 
parathyroid cells. 
 RNAi is an evolutionarily conserved 
mechanism developed for protection 
against viruses. Interfering RNAs are 
short molecules (20 – 25 nucleotides) gen-
erated from the fragmentation of larger 
precursors.  ere are three major catego-
ries of interfering RNAs ( Figure 1 ) 
(reviewed by Grosshans and Filipowicz 8 ): 
(1) siRNAs are the products of long dou-
ble-stranded RNA molecules processed 
by the endonuclease Dicer. Then the 
siRNAs are taken by a multimeric com-
plex called the RNA-induced silencing 
complex (RISC).  e RISC is guided by 
the integrated siRNA to identify homo-
logous mRNAs for subsequent cleavage. 
(2) Micro-interfering RNAs (miRNAs) are 
encoded in the genome. AN er transcrip-
tion, the pre-miRNAs are folded as 
intramolecular hairpins.  ese are proc-
essed by Dicer to form miRNAs, which 
are incorporated into the RISC to search 
for the mRNA target. (3) Piwi-interacting 
RNAs (piRNAs) are generated from large 
single-stranded molecules in a Dicer-
independent process; their functions are 
unknown . 
 The therapeutic utility of siRNA 
came from the discovery that these syn-
thetic short molecules can be delivered 
exogenously or expressed endogenously 
to drive the speci c downregulation of a 
target mRNA. siRNAs ’ silencing of genes 
has been instrumental in determining the 
role of menin (the product of the MEN-1 
gene) in the development of parathyroid 
tumorigenesis. 9 
 A major obstacle to circumvent in order 
to achieve clinical application of siRNA 
hormone (PTH) production by hyper-
plastic parathyroid cells. 
  e lack of a functional parathyroid cell 
line has forced researchers to perform 
 in vitro studies in freshly isolated para-
thyroid cells. However, these cells rapidly 
lose the expression of calcium-sensing 
receptor (CaSR) and therefore the capac-
ity to respond to changes in extracellular 
calcium. Some functional properties of 
parathyroid cells were demonstrated only 
when the three-dimensional structure of 
the parathyroid tissue was preserved. A 
direct e/ ect of phosphate on PTH secre-
tion remained elusive until the use of par-
athyroid gland tissue. 2 Culturing cells in a 
manner that preserves the structure of the 
tissue helps to retain parathyroid cell 
functions  in vitro . Roussanne  et al. 3 
showed a sustained functional response 
for up to 5 months in hyperplastic human 
parathyroid cells aggregated into three-
dimensional clusters.  ere is not a clear 
explanation of why cell-to-cell interaction 
is so important; Sun  et al. 4 showed that 
parathyroid cells in close proximity are 
stimulated to secrete more PTH, suggest-
ing a paracrine interaction between 
parathyroid cells. More recently, a  ‘ pseu-
dogland ’ model of parathyroid tissue has 
been developed that also illustrates the 
importance of the three-dimensional cel-
lular architecture in order to achieve an 
adequate function of parathyroid cells in 
culture. 5 Kanai  et al. , 1 using a methodol-
ogy based on previous work by Ridgeway 
 et al. , 6 have established long-term three-
dimensional organized cell cultures, 
named  ‘ spheroids, ’ using parathyroid cells 
from patients with secondary hyperpara-
thyroidism. These spheroids show low 
proliferative activity and the expression of 
CaSR with an acceptable response to cal-
cium for up to 3 months. Further charac-
terization of the spheroid cultures will 
assist other researchers in establishing their 
own speci c experimental protocols. 
 RNA is a biological macromolecule that 
is essential for the translation of genetic 
information. Researchers are trying to 
exploit the inherent properties of RNAs 
with the purpose of interfering with or 
repairing dysfunctional nucleic acids and 
stimulating the production of therapeutic 
gene products.  e use of gene therapy 
for renal disease is being investigated 
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 Figure 1  |  RNAi strategies in gene silencing. Small interfering RNAs (siRNAs) are formed when 
long double-stranded RNA (dsRNA) molecules are processed by the endonuclease Dicer. The 
antisense strands of the siRNA are then incorporated into the multimeric RNA-induced silencing 
complex (RISC), which uses it as a guide to identify and degrade the homologous mRNAs. Micro-
interfering RNAs (miRNAs) are encoded in the genome; after transcription, the pre-miRNAs are 
folded as intramolecular hairpins and processed by Dicer to form miRNAs, which are incorporated 
into the RISC to search for the mRNA target either to degrade it or to disable its translation. 
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therapy is the di.  culty of delivering these 
molecules into the cytoplasm of the target 
cells. An exception may be mucosal tis-
sues. In the lung and vagina, siRNA uptake 
is extremely e.  cient and occurs even in 
the absence of transfection reagents. E.  -
cient siRNA delivery and silencing can be 
achieved by the mixing of siRNAs with 
cationic lipid transfection reagents and 
direct injection of the siRNA – lipid com-
plexes into the relevant tissue.  e mixing 
of siRNAs with other molecules known to 
carry nucleic acids into cells, such as cer-
tain cationic peptides, might be also used 
e/ ectively for local delivery. 
 In their  in vivo studies, Kanai  et al. 1 used 
the hydrodynamic method developed for 
introducing nucleic acids systemically.  e 
rapid high-pressure intravenous injection 
( ‘ hydrodynamic method ’ ) leads to tran-
sient right-sided heart failure, where ele-
vated venous pressures enable siRNAs to 
get into cells in highly vascularized organs. 
  is is particularly e/ ective for transfect-
ing cells in the liver (the organ where the 
parathyroid cells were transplanted), pan-
creas, and lungs.  e strategy appears to be 
risky for human use. It is, however, possi-
ble to deliver siRNAs into an organ, such 
as the kidney, by injection via catheter into 
the draining vein. 
 A dose-dependent suppression of PTH 
secretion was achieved and lasted up to 50 
days.  e dose-dependency is of interest 
because in the clinical setting, it would be 
necessary to tailor the dosing regimen for 
individual patients with di/ erent levels of 
PTH. Some authors would consider the 
goal in gene therapies to be the achieve-
ment of stable transfection ; however, the 
fact is that transitory suppression (transi-
tory transfection) would facilitate the con-
trol of the dose in order to obtain a target 
PTH in individual patients. 
 Unwanted side e/ ects of RNAi tech-
niques have included the induction of 
type 1 interferon responses and saturation 
of endogenous RNAi pathway compo-
nents. 10  e issue of cell-speci c or tissue-
speci c delivery is another key challenge 
in developing RNAi-based therapies. We 
do not know the effects of siRNA in 
other tissues.  us, innovative methods to 
direct the siRNA to its target tissue need 
to be developed. siRNAs can be covalently 
or noncovalently linked to antibody frag-
ments or ligands to cell-surface receptors 
to limit the delivery of the siRNAs to cells 
that bear the specific receptor. Other 
modi cations, such as conjugated mole-
cules, will be necessary to avoid degrada-
tion of siRNA by plasma nucleases. Any 
modification in siRNA delivery will 
decrease the amount of siRNAs needed, 
and the optimal delivery strategy may 
differ between different therapeutic 
indications. 
 Some important issues need to be 
resolved before consideration of the appli-
cation of this procedure to control exces-
sive PTH production in patients.  e good 
response obtained in the spheroid cultures 
is partially due to the absence of cell pro-
liferation, which may have minimized the 
dilution of the transfected siRNA; how-
ever, parathyroid glands from patients 
with secondary hyperparathyroidism 
exhibit a relatively high rate of cell prolif-
eration.  e study by Kanai  et al. 1 was 
performed on parathyroid cells from 
patients with secondary hyperparathy-
roidism, and as the authors suggest, these 
cells have decreased nuclease activity, 
which would prolong half-lives of cyto-
plasmic siRNA . It seems necessary to per-
form additional studies even on cells from 
normal parathyroid glands; the impact of 
long-term PTH silencing on other cell 
functions, such as CaSR expression, needs 
to be investigated. 
 Recent findings have shown the 
e/ ectiveness of RNAi in therapeutically 
relevant settings, generating optimism 
about the use of RNAi-based therapies. 
Initial clinical applications of RNAi 
have been directed at the treatment of 
age-related macular degeneration and 
respiratory syncytial virus infection. 
Therapies based on RNAi are also in 
preclinical development for other viral 
diseases, neurodegenerative disorders, 
and cancers. 10 
  e countdown to the application of 
siRNA therapy for control of hyperpar-
athyroidism has started, and only time 
and research will have the  nal word on 
the clinical use of these strategies. 
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